ライフサイエンスコーパス: total parenteral nutrition

1 who were provided nutritional support using total parenteral nutrition.

2 transpyloric feeding tubes, and 7% received total parenteral nutrition.

3 ng bone marrow transplantation and receiving total parenteral nutrition.

4 tion included short-bowel syndrome requiring total parenteral nutrition.

5 tically ill neonates, and patients receiving total parenteral nutrition.

6 mia during intensive insulin therapy than is total parenteral nutrition.

7 ne dose typically administered with standard total parenteral nutrition.

8 ial barrier function that is associated with total parenteral nutrition.

9 icantly increased with the administration of total parenteral nutrition.

10 antly lower than in wild-type mice receiving total parenteral nutrition.

11 t-bowel syndrome, which required him to have total parenteral nutrition.

12 surviving graft recipients are weaned off of total parenteral nutrition.

13 asis remain complex problems for patients on total parenteral nutrition.

14 ation predicts the duration of dependence on total parenteral nutrition.

15 with (odds ratio [95% confidence interval]): total parenteral nutrition (2.79 [1.26-6.17]), dialysis

16 9418], P<0.001), and the incidence of use of total parenteral nutrition (31 percent vs. 55 percent, P

17 dence interval, 1.8 to 148.1) and receipt of total parenteral nutrition (adjusted odds ratio, 9.2; 95

18 Total parenteral nutrition administration was associated

19 ion, alcohol use, use of medications, recent total parenteral nutrition, age at symptom onset, recent

20 Seven days of total parenteral nutrition alone enhanced plasma GSH lev

21 studies indicate that copper requirements in total parenteral nutrition amount to 0.3 mg/day in the a

22 o distinct physiological differences between total parenteral nutrition and enteral nutrition that ar

23 thers do not, and why some patients tolerate total parenteral nutrition and others develop liver dysf

24 All required total parenteral nutrition and repeated albumin infusion

25 ediate care unit, chronic care requirements (total parenteral nutrition and tracheostomy), specific d

26 l of villus atrophy by the administration of total parenteral nutrition, and a model of villus hypert

27 Nonimmune animals were randomized to chow or total parenteral nutrition, and after 5 days of diet wer

28 ain triglycerides, therapeutic paracentesis, total parenteral nutrition, and somatostatins.

29 Sepsis and total parenteral nutrition-associated cholestasis remain

30 hionine are the most promising treatments of total parenteral nutrition-associated cholestasis.

31 ytosterols in parenteral lipid solutions and total parenteral nutrition-associated cholestasis.

32 tohepatitis, primary sclerosing cholangitis, total parenteral nutrition-associated liver disease, and

33 Patients with short-gut syndrome may develop total parenteral nutrition-associated liver disease, whi

34 All surviving patients weaned-off total parenteral nutrition at a median time of 32 days a

35 d glucose into the systemic circulation with total parenteral nutrition at rates that approximate usu

36 e premature infants, patients with long-term total parenteral nutrition, Crohn's disease, cystic fibr

37 lbumin to hypoalbuminemic patients receiving total parenteral nutrition does not improve morbidity or

38 tter define the parameters that best predict total parenteral nutrition failure and the unique mechan

39 isease complicated by short gut syndrome and total parenteral nutrition failure.

40 following an active infection, seven of nine total parenteral nutrition-fed animals continued to have

41 ore than or equal to 13, expected to require total parenteral nutrition for at least 5 days.

42 ept for a recipient of CLDILTx, currently on total parenteral nutrition for late fistula.

43 by carbachol and glucose were higher in the total parenteral nutrition group compared with the contr

44 Ion transport in the total parenteral nutrition group was significantly incre

45 Total parenteral nutrition has significant effects on in

46 atio, 5.8 [95% CI, 3.0 to 11.3]), receipt of total parenteral nutrition (hazard ratio, 4.1 [CI, 2.3 t

47 intra-abdominal abscess in 23 patients, and total parenteral nutrition in 74 (36%).

48 Our understanding of the effects of total parenteral nutrition in critical illness has been

49 osing cholangitis, cholestasis of pregnancy, total parenteral nutrition-induced cholestasis, and drug

50 o assess the role of interferon-gamma on the total parenteral nutrition-induced loss of epithelial ba

51 y injured patients compared with intravenous total parenteral nutrition (IV TPN) or no nutritional su

52 Total parenteral nutrition led to a loss of EBF, and thi

53 Investigations suggest that total parenteral nutrition may compromise bactericidal a

54 al permeability in interferon-gamma knockout total parenteral nutrition mice was significantly lower

55 Although there is evidence to suggest that total parenteral nutrition more effectively spares prote

56 These factors may make total parenteral nutrition more efficacious, at least in

57 rition: odds ratio, 2.65; 95% CI, 1.93-3.63; total parenteral nutrition: odds ratio, 3.27; 95% CI, 2.

58 To investigate the effect of total parenteral nutrition on intestinal ion transport,

59 Wild-type mice received total parenteral nutrition or enteral diet (control grou

60 ointestinal complications (P = 0.03), use of total parenteral nutrition (P < 0.001), and lung transpl

61 The use of total parenteral nutrition (p = 0.03), longer duration o

62 Seven were put on total parenteral nutrition plus octreotide.

63 Total parenteral nutrition (PN), including fat administe

64 Patients received total parenteral nutrition prepared either with a lipid

65 en are noted with stones in association with total parenteral nutrition, prolonged fasting, or ileal

66 comparable with patients given conventional total parenteral nutrition regimens, even when criticall

67 derwent multivisceral transplantation due to total parenteral nutrition-related liver disease.

68 Total parenteral nutrition significantly increased small

69 de shortage of injectable zinc available for total parenteral nutrition supplementation over the last

70 Total parenteral nutrition support of sham animals follo

71 uding much higher serum insulin responses to total parenteral nutrition than with enteral nutrition t

72 400 IU of vitamin D(3) and was dependent on total parenteral nutrition that contained 200 IU of vita

73 Enteral nutrient deprivation via total parenteral nutrition (TPN) administration leads to

74 d male rats (approximately 235 g) were given total parenteral nutrition (TPN) and treated with recomb

75 ntrations in hospitalized patients beginning total parenteral nutrition (TPN) and whether a 3-d regim

76 medium-chain triacylglycerols (MCTs) during total parenteral nutrition (TPN) enhanced macrophage res

77 Then the animals were maintained on total parenteral nutrition (TPN) for 10 days, after whic

78 40% to 60% of infants who require long-term total parenteral nutrition (TPN) for intestinal failure

79 cadaver donors have become an alternative to total parenteral nutrition (TPN) for the treatment of ir

80 Prior research has shown that mice fed total parenteral nutrition (TPN) have reduced GALT T and

81 Total parenteral nutrition (TPN) is an invasive and adva

82 Total parenteral nutrition (TPN) is commonly used clinic

83 Total parenteral nutrition (TPN) leads a loss of epithel

84 showed that enteral nutrient deprivation or total parenteral nutrition (TPN) led to a loss of intest

85 t bowel syndrome are maintained on long-term total parenteral nutrition (TPN) or more frequently cons

86 Both intravenous and intragastric total parenteral nutrition (TPN) produce GALT atrophy, b

87 cine tracer technique after 24 h of a stable total parenteral nutrition (TPN) regimen.

88 ich involved removal of amino acids from the total parenteral nutrition (TPN) solution for 8 h before

89 Prior work shows that mice fed total parenteral nutrition (TPN) solutions either intrav

90 ed to receive for > or = 5 d tube feeding or total parenteral nutrition (TPN) that had identical ener

91 aper we show that feeding chemically defined total parenteral nutrition (TPN) to genetically normal,

92 birth weight (VLBW) infants are dependent on total parenteral nutrition (TPN) to prevent hypoglycemia

93 e enteroplasty [STEP]) in terms of survival, total parenteral nutrition (TPN) weaning, and complicati

94 nit and receiving mechanical ventilation and total parenteral nutrition (TPN) were measured for > or

95 Patients received total parenteral nutrition (TPN) with caloric intake 20%

96 nts were females with a history of long-term total parenteral nutrition (TPN) with TPN-related choles

97 jejunal early enteral nutrition (NJEEN) with total parenteral nutrition (TPN), after pancreaticoduode

98 essional interest, with special reference to total parenteral nutrition (TPN), an area in which I hav

99 occurrence of significant infection, days of total parenteral nutrition (TPN), and days of injectable

100 ics and antifungals, and ICU factors such as total parenteral nutrition (TPN), blood product transfus

101 In several models, including rats given total parenteral nutrition (TPN), IGF-I more potently st

102 We utilized a model of total parenteral nutrition (TPN), or enteral nutrient de

103 a model of enteral nutrient deprivation, or total parenteral nutrition (TPN), resulting in intestina

104 Mice that received total parenteral nutrition (TPN), which deprives the ani

105 inal failure patients do well with long-term total parenteral nutrition (TPN), while others develop l

106 Total parenteral nutrition (TPN), with the complete remo

107 He recovered from PTLD but developed total parenteral nutrition (TPN)-induced liver failure.

108 liver disease (one), A-1-A deficiency (one), Total Parenteral Nutrition (TPN)-related (one), cryptoge

109 ied in a model of mucosal atrophy induced by total parenteral nutrition (TPN).

110 opment of gut failure (GF) with the need for total parenteral nutrition (TPN).

111 ctly into the veins of rats by the method of total parenteral nutrition (TPN).

112 nal inflammation are common complications of total parenteral nutrition (TPN).

113 thyroid gland function in patients receiving total parenteral nutrition (TPN).

114 port was provided to rats for 7 days by oral total parenteral nutrition (TPN; elemental diet) 307 kca

115 , and judicious jejunostomy tube feeding, or total parenteral nutrition usage may reduce morbidity.

116 3.8 years, and time from ITx to cessation of total parenteral nutrition was 31 days.

117 Total parenteral nutrition was discontinued 1 week postt

118 The percentages of infants who depended on total parenteral nutrition were 17 of 36 (47.2 percent)

119 , tumor size larger than 10 cm, and need for total parenteral nutrition were shown to further define

120 standard therapy for short bowel syndrome is total parenteral nutrition, which is expensive and assoc

121 Patients received total parenteral nutrition with standard (1.5 g . kg(-1)